H Daniel Perez MD
Co-Founder, CEO and Chairman
During his twenty-four years in the pharmaceutical industry, Dr Perez has developed wide-ranging experience driving R&D operations, clinical trials, collaborations, licensing deals, spin-outs and acquisitions. He has published extensively and has been elected to multiple scientific societies and Boards.
Co-Founder, CFO and COO
Mr Bagnall has held c-suite positions in public and private biotechnology companies for more than 20 years. During that time, he negotiated and managed five M&A transactions, raised more than $250 million in equity and debt financings and negotiated numerous licensing agreements.
Mark Pimentel MD FRCPC
Chairman of the Naia Rare Diseases Advisory Board; Director of the Gastrointestinal Motility Program and Laboratory at Cedars-Sinai Medical Center.
Mark DeLegge MD FACG CNSP AGAF FASGE
Medical University of South Carolina in Charleston
John DiBaise MD
Professor of Medicine, Mayo Clinic, Scottsdale
Stuart Kaufman MD
Medical Director, Pediatric Transplantation, Georgetown Medical Center
Farooq Rahman BSc PhD FRCP
Consultant Gastroenterologist & Lead Physician for Intestinal Failure, University College Hospital, London
Prof Palle Bekker Jeppesen MD PhD
Head of Research at the Department of Gastroenterology, Rigshospitalet, Copenhagen
Formerly Regional Business Director, Rare Disease – Shire and NPS
CEO, Short Bowel Syndrome Foundation